Challenges in the sequencing of therapies for the management of metastatic castration-resistant prostate cancer

Phillip Parente, Francis Parnis, Howard Gurney

Research output: Contribution to journalReview articleResearchpeer-review

Abstract

Prior to 2010, docetaxel was the standard option for chemotherapy in men with metastatic castration-resistant prostate cancer (mCRPC). Today, the picture is vastly different: several additional therapies have each demonstrated a survival benefit such that we now have chemotherapy (cabazitaxel), androgen suppressive agents (abiraterone acetate and enzalutamide), a cellular vaccine (sipuleucel-T) and radium-233 (for symptomatic bone metastases). With several other agents in the pipeline for late-stage disease, the future looks promising for mCRPC. As the available data are not able to inform as to the optimum sequencing of therapy, this remains a challenge. This paper draws on insights from published and ongoing clinical studies to provide a practical patient-focused approach to maximize the benefits of the current therapeutic armamentarium. Preliminary sequencing suggestions are made based on clinical trial criteria. But until more data become available, clinical gestalt, experience, cost and individual patient preferences will continue to drive choices.

LanguageEnglish
Pages205-215
Number of pages11
JournalAsia-Pacific Journal of Clinical Oncology
Volume10
Issue number3
DOIs
Publication statusPublished - 2014
Externally publishedYes

Fingerprint

Castration
Prostatic Neoplasms
docetaxel
Drug Therapy
Radium
Patient Preference
Androgens
Therapeutics
Vaccines
Clinical Trials
Neoplasm Metastasis
Costs and Cost Analysis
Bone and Bones
Survival

Keywords

  • Abiraterone acetate
  • Cabazitaxel
  • Enzalutamide
  • Innovative therapy
  • Prostate cancer

Cite this

@article{6de869c1dd6b43b7b48cf3c7cb25229a,
title = "Challenges in the sequencing of therapies for the management of metastatic castration-resistant prostate cancer",
abstract = "Prior to 2010, docetaxel was the standard option for chemotherapy in men with metastatic castration-resistant prostate cancer (mCRPC). Today, the picture is vastly different: several additional therapies have each demonstrated a survival benefit such that we now have chemotherapy (cabazitaxel), androgen suppressive agents (abiraterone acetate and enzalutamide), a cellular vaccine (sipuleucel-T) and radium-233 (for symptomatic bone metastases). With several other agents in the pipeline for late-stage disease, the future looks promising for mCRPC. As the available data are not able to inform as to the optimum sequencing of therapy, this remains a challenge. This paper draws on insights from published and ongoing clinical studies to provide a practical patient-focused approach to maximize the benefits of the current therapeutic armamentarium. Preliminary sequencing suggestions are made based on clinical trial criteria. But until more data become available, clinical gestalt, experience, cost and individual patient preferences will continue to drive choices.",
keywords = "Abiraterone acetate, Cabazitaxel, Enzalutamide, Innovative therapy, Prostate cancer",
author = "Phillip Parente and Francis Parnis and Howard Gurney",
year = "2014",
doi = "10.1111/ajco.12193",
language = "English",
volume = "10",
pages = "205--215",
journal = "Asia-Pacific Journal of Clinical Oncology",
issn = "1743-7555",
publisher = "Wiley-Blackwell, Wiley",
number = "3",

}

Challenges in the sequencing of therapies for the management of metastatic castration-resistant prostate cancer. / Parente, Phillip; Parnis, Francis; Gurney, Howard.

In: Asia-Pacific Journal of Clinical Oncology, Vol. 10, No. 3, 2014, p. 205-215.

Research output: Contribution to journalReview articleResearchpeer-review

TY - JOUR

T1 - Challenges in the sequencing of therapies for the management of metastatic castration-resistant prostate cancer

AU - Parente, Phillip

AU - Parnis, Francis

AU - Gurney, Howard

PY - 2014

Y1 - 2014

N2 - Prior to 2010, docetaxel was the standard option for chemotherapy in men with metastatic castration-resistant prostate cancer (mCRPC). Today, the picture is vastly different: several additional therapies have each demonstrated a survival benefit such that we now have chemotherapy (cabazitaxel), androgen suppressive agents (abiraterone acetate and enzalutamide), a cellular vaccine (sipuleucel-T) and radium-233 (for symptomatic bone metastases). With several other agents in the pipeline for late-stage disease, the future looks promising for mCRPC. As the available data are not able to inform as to the optimum sequencing of therapy, this remains a challenge. This paper draws on insights from published and ongoing clinical studies to provide a practical patient-focused approach to maximize the benefits of the current therapeutic armamentarium. Preliminary sequencing suggestions are made based on clinical trial criteria. But until more data become available, clinical gestalt, experience, cost and individual patient preferences will continue to drive choices.

AB - Prior to 2010, docetaxel was the standard option for chemotherapy in men with metastatic castration-resistant prostate cancer (mCRPC). Today, the picture is vastly different: several additional therapies have each demonstrated a survival benefit such that we now have chemotherapy (cabazitaxel), androgen suppressive agents (abiraterone acetate and enzalutamide), a cellular vaccine (sipuleucel-T) and radium-233 (for symptomatic bone metastases). With several other agents in the pipeline for late-stage disease, the future looks promising for mCRPC. As the available data are not able to inform as to the optimum sequencing of therapy, this remains a challenge. This paper draws on insights from published and ongoing clinical studies to provide a practical patient-focused approach to maximize the benefits of the current therapeutic armamentarium. Preliminary sequencing suggestions are made based on clinical trial criteria. But until more data become available, clinical gestalt, experience, cost and individual patient preferences will continue to drive choices.

KW - Abiraterone acetate

KW - Cabazitaxel

KW - Enzalutamide

KW - Innovative therapy

KW - Prostate cancer

UR - http://www.scopus.com/inward/record.url?scp=84906244073&partnerID=8YFLogxK

U2 - 10.1111/ajco.12193

DO - 10.1111/ajco.12193

M3 - Review article

VL - 10

SP - 205

EP - 215

JO - Asia-Pacific Journal of Clinical Oncology

T2 - Asia-Pacific Journal of Clinical Oncology

JF - Asia-Pacific Journal of Clinical Oncology

SN - 1743-7555

IS - 3

ER -